What's Happening?
Citius Oncology, a subsidiary of Citius Pharmaceuticals, has entered into a distribution agreement with McKesson Corporation for the U.S. distribution of LYMPHIR, a novel immunotherapy approved by the FDA
for treating relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL). This agreement completes Citius Oncology's U.S. distribution network, ensuring broad access to LYMPHIR ahead of its commercial launch in late 2025. McKesson, a leading pharmaceutical distributor, will play a crucial role in making LYMPHIR available to healthcare providers and patients across the country.
Why It's Important?
The partnership with McKesson is significant as it ensures that LYMPHIR, a targeted immune therapy, will be widely accessible to patients suffering from CTCL, a type of non-Hodgkin lymphoma. This collaboration is expected to enhance Citius Oncology's market presence and support its commitment to providing innovative cancer treatments. The distribution network's completion is a strategic milestone that positions Citius Oncology to effectively meet the needs of the CTCL community, potentially improving patient outcomes and quality of life.
What's Next?
With the distribution network in place, Citius Oncology is poised to launch LYMPHIR commercially in the fourth quarter of 2025. The company will focus on inventory readiness, market access infrastructure, and educational resources for providers and patients. The successful launch of LYMPHIR could pave the way for further advancements in Citius Oncology's pipeline, including other critical care products under development.
